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Abstract Chikungunya virus (CHIKV) is an alphavirus
transmitted by mosquitoes, mostly Aedes aegypti and Aedes
albopictus. After half a century of focal outbreaks of acute
febrile polyarthralgia in Africa and Asia, the disease
unexpectedly spread in the past decade with large outbreaks
in Africa and around the Indian Ocean and rare autochtho-
nous transmission in temperate areas. This emergence
brought new insights on its pathogenesis, notably the role
of the A226V mutation that improved CHIKV fitness in Ae.
albopictus and the possible CHIKV persistence in deep
tissue sanctuaries for months after infection. Massive
outbreaks also revealed new aspects of the acute stage:
the high number of symptomatic cases, unexpected com-
plications, mother-to-child transmission, and low lethality
in debilitated patients. The follow-up of patients in
epidemic areas has identified frequent, long-lasting, rheu-
matic disorders, including rare inflammatory joint destruc-
tion, and common chronic mood changes associated with
quality-of-life impairment. Thus, the globalization of
CHIKV exposes countries with Aedes mosquitoes both to
brutal outbreaks of acute incapacitating episodes and
endemic long-lasting disorders.
Keywords Chikungunya.Alphavirus.Rheumatism.
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Introduction
The chikungunya virus (CHIKV) is an arthropod-borne
virus transmitted by Aedes mosquitoes that is mostly
responsible for acute and chronic articular manifestations
[1•]. It has become a new, unexpected public health
problem in many tropical African and Asian countries
within the past decade, and is now considered a real threat
to temperate areas colonized by Aedes spp, such as Europe
and the Americas [1•]. First described in Africa (Tanzania)
in 1954 and then identified in Asia, it was responsible for
widespread outbreaks on these two continents from the
1960s to the 1980s, before a period of relative quiescence
over the following 20 years. In 2000, a huge outbreak in the
Congo [2] announced a resurgence of the disease, and its
global emergence really started in 2004. A major outbreak
first spread from Eastern Africa, in Kenya, to most islands
in the Indian Ocean in 2005–2006 [3], notably infecting
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CHIKV spread progressively toward Asia, affecting India
since 2006 [5] and successively most countries of the
region. Hundreds of intercontinental travelers were also
infected while staying in epidemic countries [1•, 6, 7].
Unexpectedly, in 2007, Italy underwent a small autochtho-
nous outbreak that developed from a single viremic patient
returning from India [8]. In September 2010, in southeastern
France, two cases of autochthonous transmission of
chikungunya fever were described (Leparc-Goffart, person-
al communication) and focal transmission has been since
observed in Southern China, Arabic peninsula and New
Caledonia in Pacific Ocean. These events confirmed the
epidemic potency of this arboviral disease and definitely
showed the risk for temperate or remote areas.
With this recent global emergence witnessing millions of
infected patients, our knowledge of the disease significantly
changed. Before 2004, it was considered a minor arboviral
disease from an epidemiological and clinical point of view.
Chikungunya was mostly perceived as a benign acute painful
fever, and commonly mistaken for dengue fever. Its first
description was limited to a brutal fever, a constant peripheral
polyarthritis occasionallyassociatedwitha rash. The intensity
of the pain and handicap gave the disease its name:
“chikungunya” means “that which bends up” in Makonde
language. Studies from the recent outbreaks described the
features of the acute stage, including atypical, severe, and
lethal complications, and showed the burden of the chronic
stage [4, 9–11]. This review aims to present the pathogenesis
of CHIKV, its epidemiological changes, individual conse-
quences, and future challenges.
Chikungunya Virus: An Alphavirus and an Arbovirus
Virological Aspects and Pathogenesis
CHIKV belongs to the alphavirus genus of the Togaviridae
family [12]. It belongs to the Semliki Forest virus antigenic
complex that also contains the O’Nyong Nyong, Mayaro,
and Ross River viruses. It is an enveloped positive-strand
RNA virus, with a genome of about 12 kb. The genome is
capped in 5′ and has a polyA tail in the 3′ end. It encodes
four nonstructural proteins (nsP1 to nsP4) and five
structural proteins (C-E3-E2-6 k-E1). Genetic analysis
based on the E1 envelope glycoprotein sequences showed
three distinct lineages: the West African cluster, the East-
Central and South African cluster (ECSA), and the Asian
cluster [13]. It is thought that CHIKV originated in West
Africa, colonized other African areas, and was secondarily
introduced into Asia before the 1960s [14••]. The viral
situation remained stable for five decades. Strains circulat-
ing in the Western Indian Ocean in the 2000s were related
to the ESCA lineage [12]. The most significant event in
CHIKV history was the appearance of an adaptive
mutation, an alanine-to-valine substitution at position 226 in
the E1 glycoprotein gene (E1:A226V) on an ESCA-CHIKV
strain circulating on Reunion Island after September 2005. It
led the mutated CHIKV to lose cholesterol dependence
for growth and enhanced its infectivity, replication, and
transmission by Ae. albopictus, without impairing com-
mon vectorial capability of Ae. aegypti [15, 16]. Similar
genetic events occurred independently in India, Gabon,
and Cameroon, suggesting an evolutionary convergence of
the virus to this mosquito and a great subsequent ability
for worldwide epidemic expansion [13, 17, 18]. To date,
no difference in virulence between the different strains of
C H I K Vh a sb e e ns h o w ni nh u m a n s .
The pathophysiology of human CHIKV infection has
long been a mystery. Some hypotheses were first proposed
based on data from other alphaviruses. Significant progress
was made after studies on chikungunya animal modelsand on
target cells for CHIKV replication in humans. CHIKV could
be detected in connective tissue (especially in epimysium), in
muscle, joint, and skin fibroblasts, and even in the central
nervous system (CNS) in some severe mouse infections but
not in fetal or placental tissues [19, 20]. Nevertheless, murine
models are limited because the CHIKV infection in the
mouse does not present all the patterns of the human disease.
Labadie et al. [21••] described a promising model of CHIKV
infection in Cynomolgus macaques showing clinical and
pathological signs close to those observed in humans. In this
model, at the early stage of the disease, the organs targeted
for CHIKV replication were lymphoid tissues, liver, CNS,
joints, and muscle, and the persistence of CHIKV could be
found later in the lymphoid organs, liver, joints, and muscle,
macrophages being the main reservoir for persistent CHIKV
infection. In humans, acute CHIKVinfection is characterized
by a very early viremia at fever onset that can increase up to
10
9 to 10
12 RNA copies/mL and lasts up to 12 days [22].
CHIKV and IgM anti-CHIKV have been found in the
cerebrospinal fluid of patients with acute encephalitis [20].
In vitro studies have shown that human epithelial and
endothelial cells, primary fibroblasts, and monocyte-derived
macrophages are susceptible to CHIKV infection, whereas
activated B and T CD4
+ lymphocytes, monocytes, and
monocyte-derived dendritic cells were refractory to CHIKV
infection [23]. CHIKV was also detected in the biopsies of
muscle, joint, and dermis of infected human patients;
CHIKV antigens were mostly confined to the fibroblasts of
skeletal muscle epimysium, of the joint capsule, and of the
dermis [19, 20]. When studying muscle biopsies of two
patients with myositic syndrome (one present 3 months after
disease onset), Ozden et al. [24] found CHIKVantigens only
in human muscle progenitor cells (satellite cells). The
persistence of CHIKV and/or CHIKV-encoded components
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and biological changes in human infection, such as the slow
disappearance of anti-CHIKV IgM in the serum of patients
with long-lasting arthralgias [25]. Recent studies showed that
the immune response in the acute stage is characterized by a
rapid innate immune antiviral response with robust dendritic/
NK/CD4
+/CD8
+ activation and a paradoxically rather mild
Th1/Th2 cytokine response in both recovered and chronic
patients. In contrast, a prolonged antiviral immune
response with intense interferon-α and interleukin-12
production was present only in chronic patients [26••].
These data are consistent with the hypothesis of a
persistent viral challenge with a plausible direct contribu-
tion to synovial tissue damage. It also supports the use of
immunomodulation with disease-modifying antirheumatic
drugs for the most affected chronic patients, despite a
theoretical risk of viral reactivation [22, 26••].
Epidemiological Features
Besides being an alphavirus, CHIKV is also an arthropod-
borne virus sharing the epidemiological characteristics of
the conceptual group of arboviral diseases: transmission by
a susceptible mosquito, possible expansion in colonized
areas, and prevention using measures for vector control.
Nevertheless, in terms of individual management and
public health, any confusion with dengue fever could
weigh heavily because of the clinical and socioeconomic
consequences of CHIKVoutbreaks [1•, 10]. Two examples
illustrate the strong impact of CHIKV outbreaks. In the
Union of Comoros in 2005, about 80% of the CHIKV-
seropositive population were hospitalized or stayed at home
in bed for a mean of 6 days [27]. In India, the national
burden of the CHIKVoutbreak in 2006 was estimated to be
25,588 disability-adjusted life years, 69% of which were
attributed to persistent arthralgia [28].
During five decades (1950–2000), only two epidemio-
logical profiles of chikungunya fever were described
(Fig. 1). The classical African profile is characterized by
occasional small epidemics in rural areas similar to sylvatic
yellow fever and with little impact on public health.
Conversely, the classical Asian profile is responsible for
urban outbreaks involving rather anthropophilic mosqui-
toes, mainly Ae. aegypti as observed in dengue fever. The
situation changed rapidly in Reunion Island, where the new
A226V-CHIKV strain quickly became predominant and
generated an explosive outbreak because of its adaptation to
Ae. albopictus, a previously minor vector for CHIKV [12].
This diurnal, anthropophilic, and peridomestic mosquito
was the most prevalent vector in urban areas of the island,
conversely to other islands of the Indian Ocean. This
outbreak swept through Reunion Island at the beginning of
2006, after favorable climatic conditions for mosquito
proliferation. The brutal disorganization of the health
system (eg, overload of hospital structures, interruption of
blood donation and grafts) was rapidly followed by
difficulties in vector control, media excitement, and social
crisis [1•]. A third epidemiological profile was born,
distinct from those of Africa and Asia and having a simple
cycle well suited for invading certain urban areas (Fig. 1).
The A226V-CHIKV is highly efficient at spreading through
human populations in tropical and temperate countries
Fig. 1 Epidemiological features
of chikungunya transmission
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this global profile has been responsible for more than 2
million cases, mostly during outbreaks in the Indian Ocean,
India, and South-Eastern Asia, but also in Africa and in
Europe, whereas “only” a few hundred thousand cases were
reported for African and Asian profiles during the past five
decades. Thus, to date, numerous countries have been
concerned on three continents with outbreaks or autoch-
thonous cases of CHIKV infection, whether mutated or not
(Table 1). Hundreds of infections were recently diagnosed
in returning travelers worldwide. Any CHIKV-viremic
traveler arriving in an area colonized by Ae. albopictus or
any other competent mosquito (eg, Ae. aegypti) can be the
source of autochthonous transmission, as witnessed in
Northern Italy in 2007 [8], in southeastern France in 2010
and more recently in Yemen, China and New Caledonia
(Leparc-Goffart, personal communication). For this reason,
CHIKV infection is a threat to large parts of the world
where Aedes spp are already present or could settle under
favorable climatic conditions, especially Southern Europe,
the Americas, Caribbean and Pacific islands, and Australia
(Table 1).
Diagnosis of Chikungunya Disease
Laboratory diagnosis relies upon the detection of the virus
on early samples and/or specific anti-CHIKV IgM and IgG
on blood samples.
Numerous quantitative reverse transcription-polymerase
chain reactions (RT-PCR) have been developed for CHIKV
detection. Commercial kits are available, sometimes with
excellent sensitivity and specificity [29]. CHIKV-RNA is
detected in plasma samples within the first week after
symptom onset, commonly with extremely high levels of
viremia [22]. RT-PCR can also be used to screen various
fluids and tissues, including corneas or other graft tissues.
CHIKV can also be isolated from early samples on C6/36
or Vero cell lines. This method is only performed in
Biosafety Level 3 laboratories, and is therefore mainly used
for epidemiological purposes and research studies.
Anti-CHIKV antibodies can be detected in patients
shortly after symptom onset, usually after 5 days for IgM
and only a few days later for IgG. Commercial enzyme
immunoassays and immunofluorescence assays are avail-
able, but are of poor performance when expertized [30•].
Interpretation of serological results must be cautious
because of 1) possible false negativity due to CHIKV-
induced mixed cryoglobulinemia [25], 2) cross-reactivity
with viruses of the Semliki Forest serocomplex requiring
seroneutralization, and 3) long-term persistence of anti-
CHIKV IgM months after disease onset. Synchronous
testing of a sample from the acute stage and a sample
collected at least 3 weeks later is sufficient to demonstrate a
recent CHIKV infection in most cases. Any doubt should
lead to a request for assistance from an expert laboratory.
The good management of patients with acute CHIKV
infection is essential for public health in susceptible areas with
current Aedes spp activity. In these areas, most health
authorities recommend prompt suspicion of imported or
autochthonous cases, adequate use of diagnostic tools, isolation
of suspect patients, rapid contact with the local health
department, and sometimes mandatory case declaration. The
final aim is to avoid epidemics spreading around the new cases.
Chikungunya Infection, a Two-Stage Disease
Acute Stage
Most patients infected with CHIKV develop acute symp-
toms, usually 2 to 6 days after the infective mosquito bite.
In Reunion Island in 2005–2006, the prevalence of
asymptomatic infections was about 5% to 10% [4]. The
first symptoms start abruptly and last for about a week
before spontaneous improvement. The acute stage is
defined as the first 10 days after disease onset [9]. The
most frequent symptoms are high fever, arthralgias, back
pain, and headache [31]. Fever is usually high, and is
poorly responsive to antipyretics. Illness is associated with
intense fatigue, anorexia, myalgias, nausea, and vomiting in
adults, and even transient confusion in elderly patients. In
Reunion Island in 2006, 47.3% of adults infected
considered their fatigue as significant or very significant,
6% were depressed, and 35.5% were demoralized during
the acute phase [10]. The acute bilateral and symmetrical
rheumatism is typically extensive and progressive within a
few days [6, 9]. Peripheral joints are frequently very
painful and swollen, especially interphalangeal joints,
wrists, and ankles. The axis and proximal joints can also
become inflamed with large joint effusions in the knees
and elbows. The intensity of the symptoms prompts most
patients to search for efficient treatment. Unfortunately, no
antiviral drug has proved effective against human CHIKV
infection [32]. Thus, the treatment of the acute stage is
limited to painkillers and nonsteroidal anti-inflammatory
drugs (NSAIDs). Their efficacy is not complete, and
adverse effects are not rare as a result of excessive self-
medication. Acetaminophen is the elective drug. Aspirin
should be avoided because of the risk of bleeding.
Although sometimes dramatically effective, systemic
corticosteroids are not recommended because of the strong
rebound effect after stopping. A transient maculopapular
rash, sometimes edematous and/or pruritic, can also be
observed on the face (Fig. 2a) and the trunk of half the
patients [9]. Miscellaneous cutaneous and mucosal
changes have been reported during the acute stage of the
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222 Curr Infect Dis Rep (2011) 13:218–228disease: photosensitivity, stomatitis, mouth ulcers, exfoli-
ative dermatitis, vesicles, bullae, and purpura [31].
Gastrointestinal symptoms are common [11]. Initial bio-
logical changes are transient leukopenia and lymphopenia,
mild thrombocytopenia, low rises in C-reactive protein,
and hepatic cytolysis [9, 11, 33]. Table 2 presents some
clinical and biological signs that can help to distinguish
chikungunya from dengue fever. After a week of intense
discomfort, pain, and incapacity, most CHIKV-infected
patients experience a significant improvement of their
condition. The fever drops, and the asthenia and joint pain
become more acceptable. This period usually lasts for 1 to
2 weeks before a very common relapse.
Beside the typical fever-arthralgias-rash association, some
clinical features and complications were recently described.
Atypical features of CHIKV infection leading to hospitaliza-
tion and/or death were prospectively recruited in Reunion
Island, reflecting their incidence, clinical aspects, and out-
come [34]. The most frequent complications involved the
CNS: convulsions, meningoencephalitis, and Guillain-Barré
syndrome; the direct role of CHIKV is evident in these early
manifestations [35]. Other severe acute complications have
been reported since 2005: myocarditis [36], fulminant
hepatitis in patients with chronic liver diseases [11],
pancreatitis, acute endocrine disorders [37], extensive epi-
dermolysis [11], kidney failures, respiratory failures, and
decompensation of cardiovascular diseases [34]. Although
minor bleedings were observed [11], CHIKV infection is no
longer considered as a viral hemorrhagic fever. CHIKV
infection in children resembles that of adults, but can
occasionally be complicated with neuropsychological
changes, including lethal meningoencephalitis, with myocar-
ditis or extensive epidermolysis [38].
Atypical and complicated features are exceptional
(<0.5% of cases) and more frequently observed in elderly
patients and/or in the presence of underlying diseases such
as hypertension, cardiovascular, or respiratory conditions
[37]. During the outbreak in Reunion Island, the mortality
rate was estimated to be 0.3% to 1%, and increased with
age, with excess deaths being observed mostly in patients
over 75 years [4, 34].
The most surprising discovery was the mother-to-child
transmission, with CHIKV neonatal infections [39]. The
risk is not negligible when considering that, in Reunion
Island in March 2006, about one pregnant woman in five
had serological markers of recent infection [4]. In India, the
risk of abortion and fetal death increased before the 22nd
week of pregnancy. There was no increased risk for
malformation [40]. Mother-to-child transmission were only
observed in near-term deliveries for CHIKV-viremic moth-
ers [39]. Under these conditions, half the neonates were
infected. Neonatal CHIKV infection was symptomatic after
4 days in one in two cases, with fever, pain, prostration,
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Curr Infect Dis Rep (2011) 13:218–228 223Fig. 2 a, Chikungunya infection, acute stage with edematous rash of
the face. b, Chikungunya infection, chronic stage with swollen and
stiff hands in a 55-year-old man who was infected 5 years earlier. c,
Chikungunya infection, chronic stage with bilateral calcifications of
shoulder tendons in a 36-year-old woman who was infected 18 months
previously. d, Chikungunya infection, chronic stage with inflamma-
tory osteoarthritis of the second and third metatarsophalangeal joints
on the left foot of a 43-year-old man who was infected 5 years earlier
224 Curr Infect Dis Rep (2011) 13:218–228poor feeding, diffuse pain, distal joint edema, and miscel-
laneous skin alterations (petechiae, exanthema). Viral
meningoencephalitis was the most common complication,
with pathological MRI findings and poor outcomes (death,
persistent disabilities).
Chronic Stage
After the short-lived improvement following the acute
stage, the life of the patient recently infected with CHIKV
can be impaired by early exacerbation, inflammatory
relapses, long-lasting rheumatism, and a significant loss in
the quality of life [9]. This deterioration is more frequent in
patients over 40 years of age and/or with underlying
diseases, notably rheumatic or traumatic diseases [41•].
High CHIKV viral loads in the acute stage are also
associated with the persistence of symptoms [26••].
Within the first 3 months, most patients experience a
rebound of general discomfort, inflammation in the joints
and tendons, and an increased handicap in daily life [9].
Disabilities in the extremities are from a severe polyarthritis
involving most distal joints and multiple hypertrophic
tenosynovitides that are sometimes responsible for carpal
or tarsal tunnel syndromes. Difficulties in walking and
handling objects can induce frequent and/or prolonged sick
leave. Transient vascular disorders (eg, Raynaud syndrome)
are present in one patient in six at that period [9], possibly
in relation with the concomitant presence of mixed
cryoglobulinemia [25]. Ocular changes may also develop
a few weeks after disease onset: anterior uveitis, retinitis,
episcleritis, and optic neuritis, sometimes leading to
blindness [42].
In Reunion Island, 80% to 90% of CHIKV-infected
patients complained of persistent symptoms after the first
3 months [41•, 43]. Whether this prevalence of nonrecovery
is similar in other epidemic countries remains to be
determined. However, CHIKV-induced rheumatism is the
most frequent manifestation of the chronic stage. It consists
of three clinical components, singly or in combination: 1)
distal polyarthritis or monoarthritis mildly improved with
NSAIDs, 2) frequent tenosynovitides in the hands, wrists,
or ankles, highly sensitive to short-term systemic cortico-
therapy, and 3) exacerbation of pain in previously injured
joints and bones requiring painkillers [9]. Most of the time,
chronic peripheral polyarthritis is not associated with
significant biological changes or the appearance of auto-
antibodies [9], but mild mixed cryoglobulinemia is frequent
[25]. First radiographs of the joints involved usually do not
reveal significant changes, even in disabled patients.
Relapses are common during the chronic stage, often
triggered after exposure to cold. They include mild fever,
asthenia, increased inflammation in previously involved
joints, and occasionally in new joints. Intensification of
symptomatic treatment is often necessary and additional
localized treatments and physiotherapy can be of benefit to
some patients.
The chronic stage can severely deteriorate the patient’s
quality of life for months. At 6 months, 97% of French
CHIKV-infected active adults complained of joint symp-
toms. They considered their fatigue as totally disabling in
Table 2 Main clinical and biological differences between chikungunya and dengue fever
Chikungunya Dengue
Clinical signs
Fever Common Common
Rash D1–D4 D5–D7
Retroorbital pain Rare Common
Arthralgia Constant Rare
Arthritis Common, edematous Absent
Myalgia Common Common
Tenosynovitis Common Absent
Hypotension Possible Common, D5–D7
Minor bleeding Rare Common, D5–D7
Outcome Possible Raynaud syndrome, M2–M3 Possible fatigue for weeks
Possible tenosynovitis, M2–M3
Common persistence of arthralgia for months to years
Biological changes
Thrombocytopenia Early and mild Delayed and possibly deep
D day, M month
(Adapted from Simon et al. [1•].)
Curr Infect Dis Rep (2011) 13:218–228 2254.6% of cases, very significant or significant in 42.8%, and
37.8% described their mood as demoralized, weakened in
43.9%, and normal in only 16.2% of cases [10]. Another
study showed that, on average, only 56% of 199 CHIKV-
seropositive patients considered themselves as cured
17 months after infection, being significantly longer in
older patients. Arthralgia, fatigue, depression, and sleep
disorders were twice as common in these patients as among
seronegative controls. However, the SF-12 questionnaire
evaluated the physical component of the quality of life to be
significantly lower among seropositive patients, but not the
mental component [43]. De Andrade et al. [44•] evaluated
the link between pain and quality of life in symptomatic
patients, with a main impact on mood, work, and sleep.
Over time, unexpected delayed rheumatic complications
have manifested years after acute CHIKV infection. A small
percentage of patients with persistent arthralgia develop
authentic inflammatory destructive rheumatisms [45–48].
The most common feature is a rheumatoid arthritis (RA)-
like polyarthritis following CHIKV infection. Criteria for
this new entity are the presence of anti-CHIKV IgM and
IgG antibodies, RA based on the 1987 American College
of Rheumatology criteria, no other definite diagnosis for
arthritis, and persistent arthritis symptoms from the onset
of CHIKV infection to the RA diagnosis [47••].
Bouquillard and Combe [47••] reported a series of 21
cases of severe RA after CHIKV infection in Reunion
Island. All patients were over 45 years old and most of
them developed symmetric polyarthritis (18/21) within an
average of 10 months. The biological characteristics of the
disease were significant systemic inflammation, the pres-
ence of rheumatoid factors and HLA DRB1*04 or 01
alleles in more than half the patients, and variability of anti-
CCP antibodies. Erosions and/or joint space narrowing
were present on initial radiographs of hands and feet in half
the patients. During a 2-year follow-up, most patients
received systemic corticotherapy and were treated with
disease-modifying antirheumatic drugs (DMARDs), mostly
methotrexate (19/21) and tumor necrosis factor blockers
(6/21). Other forms of joint destruction have been described,
such as the severe relapse of previously well-controlled
psoriatic arthritis, entesopathies, or periostitis [22, 45, 48].
MRI scans seem sensitive in detecting early changes in joints
and tendons in CHIKV-induced rheumatism [46]. This could
prompt intensification of therapy, including the use of
DMARDs, if validated by further studies. To date, there is
no evidence of viral reactivation in patients treated with such
immunosuppressive drugs, but the benefits/risks balance
must be cautiously and regularly evaluated for each patient.
However, if indicated for a patient with post-CHIKV
destructive arthritis, prescription of a first-line treatment with
methotrexate should not be excluded just because of the viral
origin of the rheumatism.
Future Challenges
Scientific Progress
Despite dramatic progress in our understanding of CHIKV
infection, research must be continued into the pathogenesis
of the long-lasting osteoarticular involvement. Studies
should determine whether viral tissue sanctuaries exist in
all chronic patients or not, and if any drug could help the
immune system to eliminate CHIKV and improve patients.
In parallel with the search for efficient antiviral drugs, a
new strategy is being developed with human anti-CHIKV
immunoglobulins. Specific immunoprophylaxis or immu-
notherapy could provide a rapid antiviral action for persons
at risk of severe acute CHIKV disease, notably neonates
born from viremic mothers [49•].
Management of CHIKV-Infected Patients
The most important challenge is to reduce chronic pain and
handicap during the chronic stage of the disease. Neuro-
pathic pains in persistently symptomatic patients require a
specific pharmacological approach in regard to their
association with a more aggressive clinical picture, and
their impact on the quality of life [44•]. While awaiting
future antiviral therapy for the chronic stage, an urgent need
exists to study the efficacy and safety of corticotherapy and
DMARDs, especially methotrexate, to establish a strategy
for the early treatment of destructive arthritis.
Globalization and Prevention
The size and speed of international population movements
and the progressive worldwide dissemination of the tiger
mosquito increase the risk of new epidemic emergence of
CHIKV. International collaboration in preparedness and
response to CHIKV introduction in susceptible regions
should limit this threat. Controls in epidemic countries can
be improved by prompt vector control and the isolation of
infective patients under bednets, efficient action that is still
neglected. To date, there is no commercial vaccine against
CHIKV. Because of the possible risk of viral persistence,
live CHIKV vaccines have been abandoned in favor of new
candidates such as consensus-based DNA vaccines [50].
Conclusions
Within less than a decade, CHIKV has become a new giant
among arboviral diseases, next to dengue fever. This
emergence is mostly the result of viral evolutionary
convergence with Ae. albopictus. This epidemiological
change has led to its global expansion, supported by the
226 Curr Infect Dis Rep (2011) 13:218–228faster transport of CHIKV-viremic travelers to susceptible
areas with Aedes spp activity. In epidemic countries,
CHIKV is responsible for brutal outbreaks of febrile
episodes, and, unlike dengue fever, for endemic chronic
rheumatic disorders, the treatment and outcome of which
remain uncertain. CHIKV raises modern challenges in
science, patient care, and public health that should be
promptly taken up to limit its current rapid spread and
major consequences.
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